- Else (BABY) has produced the first whole-plant soy-free infant formula in advance of FDA approval
- Initial production will be tested for safety and to validate nutritional benefits
- The company expects its infant formula to become its flagship product
- Else Nutrition is an Israel-based food and nutrition company
- Else (BABY) is up by 3.7 per cent trading at $1.40 per share
Else (BABY) has produced the first whole-plant soy-free infant formula in advance of FDA approval.
The patent-protected formula was developed to meet Clean Label Certification guidelines and global regulations and clinical requirements for infant nutrition.
Initial commercial production, completed last month, will be used in key clinical studies for the U.S. market to validate product safety and benefits for regulatory approval.
The company anticipates its infant formula to grow into its flagship product.
Else Nutrition is an Israel-based food and nutrition company
Else (BABY) is up by 3.7 per cent trading at $1.40 per share as of 9:37 am EST.
